Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE:002399)

China · Delayed Price · Currency is CNY

9.83

-0.06 (-0.61%)

Sep 4, 2026, 3:04 PM CST

Market Cap	13.06B -23.7%
Revenue (ttm)	5.24B -0.4%
Net Income	202.92M -49.9%
EPS	0.14 -49.9%
Shares Out	1.47B
PE Ratio	71.08
Forward PE	16.95
Dividend	0.15 (1.47%)
Ex-Dividend Date	Jun 18, 2026

Volume	4,271,120
Open	10.51
Previous Close	9.89
Day's Range	9.81 - 10.51
52-Week Range	8.50 - 13.33
Beta	0.27
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHE:002399

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1998

Employees 2,150

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 002399

Full Company Profile

Financial Performance

In 2025, SHE:002399's revenue was 5.48 billion, an increase of 3.75% compared to the previous year's 5.28 billion. Earnings were 349.49 million, a decrease of -45.96%.

Financial Statements